Patients who qualify for intermediate size patient population expanded access typically have serious or life-threatening conditions, such as various forms of cancer. They must have no comparable or satisfactory alternative treatment options available. Additionally, the patient's healthcare provider must determine that the potential benefits of the investigational drug outweigh the potential risks.
